Friday, 22 November 2024

Predictive Maintenance Market Challenges: Addressing Data Security and Integration Issues

 The global predictive maintenance market size is projected to reach USD 60.13 billion by 2030, registering a CAGR of 29.5% from 2023 to 2030, according to a new study by Grand View Research, Inc. The advancement in technologies such as AI and ML has been a major factor in driving the growth of the predictive maintenance market over the forecast period. AI and ML technologies enable analysing historical data, identifying patterns, and offering accurate machine failure and maintenance predictions. AI technology will continue to improve over time as it receives more data, thereby helping improve the accuracy and reliability of predictive maintenance solutions, which would help companies reduce machinery breakdown and halt production, which helps improve operational efficiency and productivity.

 

The application of predictive maintenance solutions in industries such as healthcare, energy, transportation, and others has been another major factor driving the market's growth, as many companies started recognizing the potential benefits of installing predictive maintenance solutions. Companies are opting for digital transformation to ensure operational excellence; this trend will further accelerate the adoption of the predictive eminence solution, which is integrated with technologies such as IoT, AI, and ML. However, this limitation includes concerns regarding data price, complex interaction processes, and skill gaps, among others.

 

Gather more insights about the market drivers, restrains and growth of the Global Predictive Maintenance Market

 

Predictive Maintenance Market Report Highlights


• The service segment is projected to witness the highest CAGR of 31.0% from 2023 to 2030. The growth of the service segment can be attributed to service providers using numerical evaluation to create predictive models that predict equipment breakdowns and servicing needs.

• The integrated segment is projected to witness the highest CAGR of 29.5% from 2023 to 2030. The growth of the integrated segment can be attributed to ERP and CRM integrated solutions enabling improved efficiency and productivity.

• The training & consulting segment is projected to witness the highest CAGR of 31.5% from 2023 to 2030. The growth of the training & consulting segment can be attributed to a customized predictive maintenance strategy to enable catering to a wide range of businesses considering factors such as the machinery being used, maintenance information, and workflow, among others.

• The cloud segment is projected to witness the highest CAGR of 37.9% from 2023 to 2030. The growth of the cloud segment can be attributed to the ability to analyse large volumes and data and offer accurate information on the expected machinery failure maintenance/repair schedule, among others.

• Small and medium enterprises are projected to witness the highest CAGR of 31.6% from 2023 to 2030. The small and medium enterprises' growth can be attributed to the lower cost of cloud-based predictive maintenance solutions, enabling small and medium enterprises to avoid upfront investment into IT infrastructure.

• The oil analysis segment is projected to witness the highest CAGR of 31.5% from 2023 to 2030. The growth of the oil analysis segment can be attributed to information provided by the predictive penitence solution, including oil change, contamination, and changes in other chemical properties, among others.

• The aerospace & defense segment is projected to witness the highest CAGR of 30.6% from 2023 to 2030. The growth of the aerospace & defense segment can be attributed to AI and ML integrated predictive maintenance solution ability to proactively monitor the health of the asset, predict potential failure, and schedule repair & maintenance, among others.

• The Asia Pacific region is projected to witness the highest CAGR of 31.8% from 2023 to 2030. The growth of the Asia Pacific region can be attributed to increasing purchasing power, improving digital infrastructure, availability of cheaper predictive mainline solutions owing to the easy availability of raw materials, and advancement in 5G technology, among others.

• The companies in the predictive maintenance market have been coming up with strategic initiatives such as partnerships and mergers, among others, aimed at gaining traction in the market. For instance, in February 2023, Boon Logic, a provider of AI-based solution detectors, partnered with Software AG as a Premier member of the latter company’s PartnerConnect partner program to provide AI-enabled high-speed prediction service conditions for all complex assets. Through this partnership, the firms aimed to provide valuable insights related to the health and status of equipment to avoid failures.

 

Browse through Grand View Research's Next Generation Technologies Industry Research Reports.


• The global gaming peripheral market size was estimated at USD 6,215.0 million in 2024 and is projected to grow at a CAGR of 11.0% from 2025 to 2030.

• The global intelligent document processing market size was estimated at USD 2.30 billion in 2024 and is projected to grow at a CAGR of 33.1% from 2025 to 2030.

 

Segments Covered in the Report

 

Grand View Research has segmented the global predictive maintenance market on the basis of component, solution, service, deployment, enterprise size, monitoring technique, end use and region:

 

Predictive Maintenance Component Outlook (Revenue, USD Billion; 2018 - 2030)

  • Solution

  • Service

 

Predictive Maintenance Solution Outlook (Revenue, USD Billion; 2018 - 2030)

  • Integrated

  • Standalone

 

Predictive Maintenance Service Outlook (Revenue, USD Billion; 2018 - 2030)

  • Integration and Deployment

  • Support & Maintenance

  • Training & Consulting

 

Predictive Maintenance Deployment Model Outlook (Revenue, USD Billion; 2018 - 2030)

  • Cloud

  • On-premise

 

Predictive Maintenance Enterprise Size Outlook (Revenue, USD Billion; 2018 - 2030)

  • Small & Medium Enterprises

  • Large Enterprises

 

Predictive Maintenance Monitoring Technique Outlook (Revenue, USD Billion; 2018 - 2030)

  • Torque Monitoring

  • Vibration Monitoring

  • Oil Analysis

  • Thermography

  • Corrosion Monitoring

  • Others

 

Predictive Maintenance End Use Outlook (Revenue, USD Billion; 2018 - 2030)

  • Aerospace & Defense

  • Automotive & Transportation

  • Energy & Utilities

  • Healthcare

  • IT & Telecommunications

  • Manufacturing

  • Oil & Gas

  • Others

 

Predictive Maintenance Regional Outlook (Revenue, USD Billion; 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • China

    • India

    • Japan

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina
  • Middle East & Africa

    • UAE

    • Saudi Arabia

    • South Africa

 

Order a free sample PDF of the Predictive Maintenance Market Intelligence Study, published by Grand View Research.

 

Cell Culture Market Insights: Impact of Biotechnology Advancements

The global cell culture market size is expected to reach USD 39.09 billion by 2030 and is expected to grow at a CAGR of 11.32% from 2023 to 2030, according to a new report by Grand View Research, Inc. The novel three-dimensional cell culture techniques and the growing need for them in biopharmaceutical development, vaccine production, and the rising global demand for advanced therapy medicinal products are expected to drive the market during the forecast period. The COVID-19 pandemic has increased vaccine development activities, especially in the novel mRNA and DNA vaccines space. Vaccine production at a large scale generates a high demand for vectors produced using cell culture techniques. For instance, in February 2023, SK Bioscience announced that its first cell culture-based quadrivalent influenza vaccine, SKYCellflu, was officially licensed in South America by Instituto de Salud Publica de Chile (Institute of Public Health, ISP).


Furthermore, vaccine development requires several expression analyses, quality control, and safety testing procedures, which use cell-based assays. As a result, the usage of cell culture products for such applications has witnessed high demand in recent years. In addition, with an increase in the incidence of infectious diseases, a rise in focus on prevention of disease outbreaks, and high R&D investments in vaccine technologies, vaccine production is projected to gain traction and boost market growth.Moreover, cell culture technology has witnessed significant advancements over the past few years and the technology is witnessing a rapid expansion in its scope of applications. In the field of biopharmaceuticals, researchers can now produce complex protein-based drugs in large quantities due to the ability to culture mammalian cells.


Gather more insights about the market drivers, restrains and growth of the Global Cell Culture Market

 

This has led to increased efficiency, reduced costs, and improved quality control in the biopharmaceutical industry. Furthermore, the launch of high-yield cell lines and the optimization of culture conditions have contributed to enhanced productivity and scalability. For instance, in June 2023, Matica Bio launched its MatiMax cell lines at the BIO International Convention. Furthermore, several companies are engaged in strategic initiatives, such as market expansion, which can be attributed to market growth. For instance, in March 2021, Thermo Fisher Scientific, Inc. announced its expansion plans by investing USD 600 million into capital investments through 2022. Its cell culture media and process liquid sites in Scotland, Florida, and New York increased the production capacity of Gibco cell culture media, process liquids, and supplements. Such developments are expected to propel the market growth over the forecast period.

 

Cell Culture Market Report Highlights

 

• The consumables product segment accounted for the largest share of 57.44% in 2022 due to increased R&D spending by pharmaceutical & biopharmaceutical businesses to produce advanced biopharmaceuticals, such as monoclonal antibodies, vaccines, and cell & gene therapies

• The biopharmaceutical production segment accounted for the largest share of 32.15% in 2022. The biotechnology sector is anticipated to expand, fueling demand for cell culture supplies and instruments over the forecast period

• North America dominated the market with a share of 35.90% in 2022. The large share can be attributed to the region’s well-established pharmaceutical & biotech sectors and higher adoption of technologically advanced solutions in the U.S. In addition, there is a large market for cell culture technologies in the region due to the extensive cell therapy research efforts undertaken by several universities

• Asia Pacific is projected to expand at the fastest CAGR of 13.79% over the forecast period due to the rising awareness regarding cell and gene therapies, and the rapid adoption of scientific technologies and emerging therapeutics, such as regenerative medicines and cancer immunotherapies

 

Browse through Grand View Research's Biotechnology Industry Research Reports.


• The global proteomics market size was estimated at USD 24.29 billion in 2023 and is projected to grow at a CAGR of 13.10% from 2024 to 2030.

• The global laser capture microdissection market size was estimated at USD 189.3 million in 2023 and is expected to grow at a CAGR of 8.37% from 2024 to 2030.

 

Segments Covered in the Report

 

Grand view research has segmented the global cell culture market based on product, application, and region:

 

Cell Culture Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Consumables

    • Sera

      • Fetal Bovine Serum

      • Other

    • Reagents

      • Albumin

      • Others

    • Media

      • Serum-free Media

        • CHO Media

        • HEK 293 Media

        • BHK Medium

        • Vero Medium

        • Other Serum-free Media

      • Classical Media

      • Stem Cell Culture Media

      • Chemically Defined Media

      • Specialty Media

      • Other Cell Culture Media

  • Instruments

    • Culture Systems

    • Incubators

    • Centrifuges

    • Cryostorage Equipment

    • Biosafety Equipment

    • Pipetting Instruments

 

Cell Culture Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Biopharmaceutical Production

    • Monoclonal Antibodies

    • Vaccines Production

    • Other Therapeutic Proteins

  • Drug Development

  • Diagnostics

  • Tissue Culture & Engineering

  • Cell & Gene Therapy

  • Toxicity Testing

  • Other Applications

 

Cell Culture Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

 

Order a free sample PDF of the Cell Culture Market Intelligence Study, published by Grand View Research.

 

About Grand View Research


Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

 

Wednesday, 20 November 2024

Clinical Trial Biorepository & Archiving Solutions Market: Strategies for Optimizing Sample Storage

The global market for clinical trial biorepository and archiving solutions was valued at $4 billion in 2023 and is projected to grow at an annual rate of 8.17% from 2024 to 2030. This growth is primarily driven by pharmaceutical companies outsourcing their R&D activities to enhance their core competencies. Additionally, the economic benefits of outsourcing, such as reduced costs compared to investing in cold storage equipment, are also contributing to the market's expansion. However, keeping up with evolving storage and transportation technologies, global regulatory requirements, and current bio-storage trends can be both time-consuming and costly.


Contract Research Organizations (CROs) are experiencing significant revenue growth due to increasing R&D expenditures and the growing focus of pharmaceutical companies on developing novel drugs at reduced costs. Biopharmaceutical companies are increasingly outsourcing their clinical trials to CROs to accelerate product development and reduce costs. This trend is likely to continue as CROs become more capable of handling complex research, thereby reducing the additional efforts required by biopharmaceutical companies to monitor complex clinical trial processes.

 

Gather more insights about the market drivers, restrains and growth of the Clinical Trial Biorepository & Archiving Solutions Market

 

Regional Insights:

 

North America Clinical Trial Biorepository & Archiving Solutions Market Trends

North America held the largest market share in 2023, accounting for 47.99%. This significant share is driven by the surge in clinical trials and the expansion efforts of multiple market players in the region. Additionally, the availability of advanced technology, as exemplified by Thermo Fisher Scientific's expansion of central laboratory operations in the U.S. in June 2024, is further propelling the region's market growth.

U.S.

The U.S. holds the largest share of the North American clinical trial biorepository and archiving solutions market. This growth is fueled by two key factors: a surge in clinical trials and a booming market for companies offering related services. Looking at the numbers, a significant portion of global clinical trials take place in the U.S. Data from Atlassciences LA, current as of July 2022, shows that out of 422,201 registered studies on ClinicalTrials.gov, a staggering 32% were conducted within the U.S. This high volume of clinical activity translates to a strong demand for biorepository and archiving solutions.

Furthermore, the U.S. boasts a robust presence of Contract Research Organizations (CROs) like Quintiles, Covance, Inc., and PAREXEL International Corporation. These CROs offer a comprehensive range of services, including biorepository and archiving solutions, which further contributes to the market's growth in the U.S.

 

Asia Pacific Clinical Trial Biorepository & Archiving Solutions Market Trends

The clinical trial biorepository and archiving solutions market in the Asia Pacific region is poised for significant growth, with an expected compound annual growth rate (CAGR) of 14.22% during the forecast period. This robust growth is fueled by the ongoing expansion and advancement of clinical research activities within the region.
Several factors contribute to this market's dynamism. The relatively low cost per patient in Asia Pacific countries and the availability of a diverse patient pool that is easily accessible for recruitment create a favorable environment for clinical trials. These factors, coupled with the increasing focus on personalized medicine and the growing need for long-term storage and analysis of biological samples, are driving the demand for efficient biorepository and archiving solutions.

 

China

China's clinical trial biorepository and archiving solutions market led the global industry in 2023. This dominance is attributed to the nation's vast and diverse patient pool, coupled with a rapidly expanding pharmaceutical sector. Additionally, positive policy shifts, including the implementation of Good Supply Practices for pharmaceutical products, are poised to further stimulate market growth within China.


India

India's clinical trial biorepository and archiving solutions market is poised for significant growth in the coming years. A key driver behind this expansion is the surge in clinical trials within the country, particularly driven by the rising prevalence of chronic diseases like cardiovascular diseases, kidney diseases, and diabetes. This increasing demand for effective treatment options necessitates robust biorepository and archiving solutions to store and analyze biological samples, thereby accelerating drug discovery and development.

 

Europe Clinical Trial Biorepository & Archiving Solutions Market Trends

The European clinical trial biorepository & archiving solutions market is poised for significant growth due to technological advancements, a surge in clinical trials, and the presence of key players offering innovative solutions. This region, particularly Germany, is leading the way with its technological advancements, high-quality clinical resources, and increasing demand for clinical trials fueled by numerous CROs.


Germany


Germany's clinical trial biorepository and archiving solutions market is poised for significant growth in 2023. This growth is primarily driven by advancements in technology and the availability of high-quality clinical resources within the country. Additionally, the increasing demand for clinical trials in Germany and the presence of several prominent Contract Research Organizations (CROs) are further fueling the market's expansion. These factors collectively contribute to the growing demand for effective biorepository and archiving solutions, ultimately driving market growth over the forecast period.

 

UK

The UK market is also projected to expand due to high demand for clinical trials and the presence of key players like Bristol Biomedical Research Center and Biocentre. These factors are driving the overall growth of the European clinical trial biorepository & archiving solutions market.

 

Browse through Grand View Research's Category Medical Devices Industry Research Reports.


• The global cervical disc prosthesis market size was estimated at USD 350.88 million in 2024 and is projected to grow at a CAGR of 12.4% from 2025 to 2030.

• The global smart medical devices market size was estimated at USD 90.55 billion in 2024 and is expected to grow at a CAGR of 12.84% from 2025 to 2030.

 

Key Companies & Market Share Insights

Several key players are strategically bolstering their market presence by offering clinical trial biorepository & archiving solutions for innovative pharmaceutical vaccines and drugs. These strategies encompass agreements, new product launches, partnerships, mergers and acquisitions/joint ventures, expansions, and other initiatives aimed at increasing market penetration, revenue, and competitive advantage, ultimately driving market growth.

 

Key Clinical Trial Biorepository & Archiving Solutions Companies

 

The following are the leading companies in the clinical trial biorepository & archiving solutions market. These companies collectively hold the largest market share and dictate industry trends.

• Medpace
• American Type Culture Collection (ATCC)
• Cell&Co BioServices (Cryoport)
• Brooks Life Sciences (Azenta, Inc.)
• Patheon (Thermo Fisher Scientific, Inc.)
• Precision Medicine Group, LLC.
• Labcorp Drug Development
• Q2 Solutions
• LabConnect
• Charles River Laboratories


Order a free sample PDF of the Clinical Trial Biorepository & Archiving Solutions Market Intelligence Study, published by Grand View Research.

Monday, 18 November 2024

Healthcare Contract Research Organization Market: The Role Of Technology In Research Efficiency

 The global market for contract research organizations (CROs) was valued at a substantial USD 50.55 billion in 2023. This market is projected to experience significant growth, expanding at a Compound Annual Growth Rate (CAGR) of 7.0% from 2024 to 2030. Several key factors are driving this growth, including increased investment in research and development (R&D) programs, a growing preference for outsourcing activities to mitigate time and cost constraints, and the expiration of patents for blockbuster drugs.

 

CRO collaborations offer a range of advanced services, leading pharmaceutical and biopharmaceutical companies to increasingly favor outsourcing projects to CROs. This trend is further fueled by the mounting pressure on drug developers to adhere to rigorous clinical data management, regulatory environments, and stringent safety standards. Healthcare and pharmaceutical companies are actively outsourcing the production of medicines and their clinical trials. The privatization of clinical trials is also on the rise, contributing to a surge in outsourcing to developing countries.

 

Many CROs are strategically expanding their global research networks to enhance customer service. A notable example is MMS, a CRO specializing in data, which announced a collaboration with the Institute for Advanced Clinical Trials (I-ACT) in February 2023. This partnership aims to accelerate the development of critical therapeutics, such as medications, vaccines, and medical devices, specifically designed for pediatric use. As part of this commitment, MMS is sponsoring I-ACT's Spin Challenge, an initiative dedicated to raising funds to support and expedite clinical trials focused on children's healthcare.

 

Preclinical CRO Market: Analyzing The Impact Of Technology On Research Efficiency- 2030

 The global preclinical CRO market, valued at USD 5.72 billion in 2023, is projected to grow at a CAGR of 8.7% from 2024 to 2030. The increased R&D budget for drug development is driving the rising demand for preclinical contract research organization (CRO) services, fueling market growth. The surge in preclinical trials involving large molecules and the need to reduce R&D expenses are further contributing to the growing demand for quality preclinical CRO services.

 

The rapid pace of preclinical studies for COVID-19 vaccines highlights the crucial role of CROs. Increasing spending on CRO services is expected to significantly boost market growth during the forecast period. The growing demand for drugs post-COVID-19, coupled with significant funding from organizations like the U.S. federal government for R&D of therapeutics and medical devices, is further contributing to market expansion.

 

Gather more insights about the market drivers, restrains and growth of the Preclinical CRO Market 

 

Regional Insights:

 

North America Electric Motor Market Trends

North America accounted for the largest share of 47.2% in 2023 owing to the presence of established CROs specializing in early drug discovery, such as Charles River Laboratories and LabCorp. The U.S. is the biggest market for preclinical trial outsourcing, as several biopharmaceutical companies prefer outsourcing their preclinical trials to CROs based in the U.S., to seek benefit from the Investigational New Drug (IND) application, approved by the FDA.

U.S.

The U.S. accounted for the highest share in the global preclinical trial outsourcing market as a large number of pharmaceutical and life sciences companies are present in this region. CROs in the country possess various capabilities such as genotoxicity and immunotoxicity testing services, which are majorly carried out in the U.S. Along with this, rapid growth in emerging areas of medicine such as personalized medicines, orphan drugs, and biosimilar is expected to propel growth of the preclinical trial outsourcing market in the U.S.

 

Asia Pacific Electric Motor Market Trends

Asia Pacific is also anticipated to grow at the fastest rate of 11.6% during the forecast period. The changing business model of MNC outsourcing and the rising cost of R&D is expected to increase preclinical outsourcing in the Asia Pacific, owing to the cost efficiency offered by CROs in countries such as India and China. Established companies located in Western Europe and the U.S. pursue analytical services, site research development, and clinical activities in the Asia Pacific region in order to reduce the cost associated with research.

Japan

Japan is considered to be one of the largest pharmaceutical markets across the globe. The growing pharmaceutical industry in Japan is contributing to the increasing demand for preclinical trial outsourcing. There has been a significant increase in the number of clinical trials being conducted in the country as the Japanese government is undertaking steps to offer regulatory support and promote clinical trials in the country. This is expected to stimulate the market for preclinical services as preclinical testing requires to be conducted in proximity to central development centers.

India

Preclinical CRO in India:The preclinical CRO market in India has experienced significant growth, driven by its cost advantage, a skilled workforce, and a favorable regulatory environment. Indian CROs offer competitive pricing, attracting international pharmaceutical and biotech companies seeking to outsource preclinical research.

 

Browse through Grand View Research's Category Medical Devices Industry Research Reports.

 

  • The global probe reprocessing market size was valued at USD 844.87 million in 2024 and is anticipated to grow at a CAGR of 10.55 % from 2025 to 2030.

 

Key Companies & Market Share Insights

The preclinical CRO market is diverse, encompassing both large, multinational CROs like Labcorp, Charles River Labs, Eurofins Scientific, and Intertek Group, and smaller, specialized CROs. Market share in this sector is influenced by factors such as the number of players, service portfolio, therapeutic expertise, geographic reach, innovation, investments, and strategic partnerships. For example, Covance, a leading drug development business under Labcorp, offers a comprehensive suite of preclinical services, including pharmacology & safety assessment, vector & cell characterization & qualification, and biodistribution testing & services. These market players often specialize in specific therapeutic areas or emerging fields like immuno-oncology and gene therapy. Their broad geographic reach enables them to provide clients with access to diverse patient populations, regulatory environments, and research expertise. 


Key Preclinical CRO Companies:


• Eurofins Scientific
• PRA Health Sciences, Inc.
• Wuxi AppTec
• Medpace, Inc.
• Charles River Laboratories International, Inc.
• PPD (Thermo Fisher Scientific, Inc.)
• SGA SA
• Intertek Group Plc (IGP)
• LABCORP
• Crown Bioscience

 

Order a free sample PDF of the Preclinical CRO Market Intelligence Study, published by Grand View Research.

Friday, 15 November 2024

Electrophysiology Devices Market: Innovations Driving Cardiac Care

 The global market for electrophysiology devices was valued at USD 12.9 billion in 2024 and is projected to expand at a Compound Annual Growth Rate (CAGR) of 15.1% from 2025 to 2030.


This growth is driven by several factors:


• Increasing use of EP tests: These tests are crucial for diagnosing and treating heart conditions like atrial fibrillation.

• Rising demand for cardiac rhythm management devices: These devices enable continuous monitoring of heart rhythms.

• Expanding applications in out-of-hospital settings: Electrophysiology devices are increasingly being used outside of traditional hospital settings. 

 

Gather more insights about the market drivers, restrains and growth of the Electrophysiology Devices Market 

 

Additionally, the prevalence of heart conditions among younger generations is on the rise due to lifestyle factors such as sedentary behavior, smoking, and excessive alcohol consumption. For instance, the Centers for Disease Control and Prevention (CDC) estimates that approximately 12.1 million Americans will be affected by atrial fibrillation by 2030.


The growing number of catheter ablation procedures is further fueling market growth. As the number of these procedures increases, so does the demand for related products and devices. Moreover, advancements in electrophysiology devices, such as improved maneuverability, flexibility, compatibility, and integrated imaging capabilities, are contributing to market expansion. An article published by Elsevier Inc. in March 2023 highlighted the significant increase in the annual rate of cardiac electrophysiology procedures in the U.S., from 817.9 per 100,000 beneficiaries in 2013 to 1,089.68 per 100,000 beneficiaries in 2019.

 

Indication Segmentation Insights 

 

Atrial fibrillation (AFib) emerged as the leading segment in the arrhythmia market in 2024, capturing a significant 73.64% revenue share. This type of arrhythmia is widely recognized as the most common, posing a substantial risk of stroke and blood clots. According to the British Heart Association, a staggering 1.5 million individuals in the UK were grappling with AFib in 2022. Alarmingly, an estimated 270,000 people aged 65 and older in the UK remained undiagnosed, contributing to the segment's substantial share.

 

The rising prevalence of AFib has spurred the development of innovative solutions, such as smartphone applications. These apps empower patients to connect with healthcare professionals, facilitating remote monitoring and timely intervention. Additionally, healthcare institutions are increasingly incorporating arrhythmia care into their treatment protocols, both in inpatient and outpatient settings. 

 

Order a free sample PDF of the Electrophysiology Devices Market Intelligence Study, published by Grand View Research.

Thursday, 14 November 2024

Vital Signs Monitoring Devices Market: Challenges and Solutions in Healthcare

 The global market for vital signs monitoring devices was valued at a substantial USD 9.2 billion in 2022. This market is projected to experience robust growth, expanding at a Compound Annual Growth Rate (CAGR) of 8.5% from 2023 to 2030. Several key factors are driving this growth, including continuous product innovation, a surge in demand for home healthcare services, a rising number of healthcare settings (particularly hospitals), and the increasing prevalence of chronic disorders.

 

Vital signs monitoring devices have undergone significant evolution, transitioning from individual devices measuring specific parameters like blood pressure, pulse, and temperature to integrated, all-in-one solutions. Moreover, the introduction of innovative products within this category is further fueling market growth.

 

Gather more insights about the market drivers, restrains and growth of the Vital Signs Monitoring Devices Market

  

The COVID-19 pandemic in 2020 accelerated the demand for vital sign monitoring devices, such as blood pressure monitors, pulse oximeters, and temperature monitoring devices. These devices became crucial tools for identifying potential COVID-19 infections by tracking key vital signs. For instance, in the U.S., where approximately 103 million people suffer from hypertension, the demand for blood pressure monitoring devices surged as COVID-19 was recognized as a significant risk for individuals with heart conditions and high blood pressure. This trend is expected to continue, with the "others" product segment in the U.S. market poised for significant growth over the forecast period.

 

End-use Segmentation Insights

 

The hospitals end-use segment accounted for the largest share of 35.4% in 2022. This is primarily due to their large patient pool and greater financing capability for these devices. These devices can now be connected to a comprehensive platform through software, allowing hospital staff to easily monitor patients’ vital signs in a single dashboard. Hospitals require all categories of vital sign monitors in large quantities, as they are needed in each room, nurse’s station, operation theater, emergency room, outpatient clinics, and in the hospital’s ambulatory services.

 

The demand for vital sign monitors in in-home healthcare settings is expected to grow as patients increasingly prefer to receive treatment and recover from surgery at home, or avail long-term care. Home healthcare is often more cost-effective than hospital stays. Additionally, developed regions like the U.S. and U.K. have streamlined policies for reimbursing home healthcare medical devices, including vital sign monitoring devices. With the rising burden of non-communicable diseases (NCDs), the demand for these devices in the home healthcare sector is likely to increase.

 

Order a free sample PDF of the Vital Signs Monitoring Devices Market Intelligence Study, published by Grand View Research.

Tuesday, 12 November 2024

Lactic Acid Market Future Innovations and Strategic Directions Report

The global lactic acid market is poised for significant growth, with an estimated value of USD 3.37 billion in 2023 and a projected CAGR of 8.0% from 2024 to 2030. This growth is primarily driven by the increasing demand for lactic acid in various end-use industries, particularly pharmaceuticals, food, and beverages, especially in emerging economies like India, China, and Indonesia.

 

Lactic acid is a versatile chemical compound with a wide range of applications. One of its primary uses is in the production of polylactic acid (PLA), a biodegradable and compostable polymer derived from renewable sources like fermentation processes. This eco-friendly nature of PLA, coupled with its safety profile as a GRAS substance recognized by the U.S. Food and Drug Administration, makes lactic acid highly attractive for the food industry. 

 

Gather more insights about the market drivers, restrains and growth of the Lactic Acid Market

 

Lactic acid can be produced through either chemical synthesis or fermentation processes. As a well-established organic acid, it finds extensive use across various industries, including food, chemicals, pharmaceuticals, and cosmetics. In the food industry, lactic acid serves as a key ingredient in numerous applications, such as winemaking, pickling, sausage production, fish curing, meat processing, vegetable preparation, baking, and the production of fermented dairy products.

 

Furthermore, lactic acid is associated with beneficial bacteria known as lactic acid bacteria (LAB). These probiotic microorganisms play a crucial role in maintaining gut health and overall well-being. Their presence in various food products contributes to their nutritional value and potential health benefits.

 

Form Segmentation Insights

 

Dry form lactic acid dominated the market in the year 2023. One of the primary drivers aiding the dry lactic acid market growth of is its usage in the formation of polylactic acid (PLA), a biodegradable polymer. PLA is widely used in packaging materials, textiles, and medical applications. Dry form is used in the formation of fermented foods such as sauerkraut, kimchi, and sour beers. It acts as a natural preservative and contributes to the unique flavors and textures of these forms. Dry form of lactic finds application in cosmetics and food & beverages industries.

 

Wet form of lactic acid is a colorless or yellow syrupy liquid with its own distinctive characteristics. It is miscible with water, forming a colorless solution when dissolved. It is used in cosmetics, skincare forms, and hair care formulations due to its exfoliating, moisturizing, and pH-regulating properties. It is also utilized in the flavors and fragrances industry as a souring agent, imparting a tangy flavor to various food and beverage forms. They are primarily used in pharmaceutical, dairy and textile industries.

 

Order a free sample PDF of the Lactic Acid Market Intelligence Study, published by Grand View Research.

Transplantation Market: The Role of Stem Cells and Regenerative Medicine

 The global transplantation market, valued at USD 15.0 billion in 2022, is poised for significant growth, projected to expand at a CAGR of 9.3% from 2023 to 2030. This growth is primarily driven by the increasing demand for innovative tissue transplantation products and organ transplantation procedures to address organ failure.

 

Organ failure, a serious medical condition, can arise from various factors including severe trauma, blood loss, poisoning, substance abuse, leukemia, sepsis, and other acute illnesses. The global demand for tissue and organ transplants, particularly kidneys, hearts, livers, and lungs, is substantial. Unhealthy lifestyle choices such as poor diet, excessive alcohol consumption, sedentary lifestyle, and drug abuse are major contributors to organ failure, further fueling the demand for transplantation products.

 

Post-transplantation surgery, recipients are often administered potent immunosuppressive drugs to prevent organ rejection. However, these medications weaken the immune system, rendering patients more vulnerable to infectious diseases. This heightened susceptibility, coupled with the challenges posed by the COVID-19 pandemic, has led to a decline in transplantation numbers in many countries. Additionally, the scarcity of essential resources like personal protective equipment, intensive care unit capacity, and blood products during the pandemic has further contributed to the market's revenue decline in 2020.

 

Gather more insights about the market drivers, restrains and growth of the Transplantation Market

 

Application Segmentation Insights

 

Tissue transplantation remains the dominant segment in the market, accounting for a substantial $79.2 billion in 2022. This prominence stems from the widespread need for replacing vital tissues such as skin, cornea, bones, heart valves, tendons, nerves, and veins. The escalating incidence of burn injuries and accidents globally is a major driver for the increasing demand for tissue products. For example, a report by the European Road Safety Observatory highlights the significant number of injury accidents in Spain, further emphasizing the need for tissue transplantation.

 

The organ transplantation segment is poised for robust growth during the forecast period. The rising number of organ transplant procedures worldwide, coupled with the recurring need for immunosuppressants, is expected to fuel market expansion. In 2017 alone, approximately 90,306 kidney transplant procedures were performed globally, underscoring the substantial demand.

 

Advancements in transplantation technology and the introduction of innovative products by manufacturers are further propelling the growth of the transplant market. This includes procedures for organs like kidneys, livers, hearts, lungs, and tissues. For instance, in November 2020, Lupin's launch of the generic immunosuppressant drug Tacrolimus in the U.S. market, indicated for preventing organ rejection in various transplant scenarios, exemplifies the ongoing innovation in this field.

 

Order a free sample PDF of the Transplantation Market Intelligence Study, published by Grand View Research.

Sunday, 10 November 2024

U.S. Peripheral Nerve Injuries Market: Patient Demographics and Treatment Awareness

The U.S. peripheral nerve injuries market is experiencing significant growth, projected to reach a value of USD 406.23 million in 2022 and expand at a CAGR of 7.32% from 2023 to 2030. This growth is primarily driven by several factors:

 

  • Aging Population: The increasing number of elderly individuals, who are more susceptible to peripheral nerve injuries, is a major contributor to market growth.
  • Rising Demand for Minimally Invasive Procedures: The preference for less invasive treatments is driving the adoption of advanced surgical techniques and tools.
  • Technological Advancements: Continuous innovation in surgical techniques and tools is enhancing the treatment of peripheral nerve injuries.
  • Growing Awareness: Increased awareness among healthcare professionals and patients regarding peripheral nerve injuries and their treatment options is fueling market demand.

 

Furthermore, significant funding from both public and private organizations is accelerating market growth. For example, Renerva, LLC, received USD 500,000 from the NIH and NSF to develop innovative techniques for peripheral nerve injuries, while NervGen Pharma Corp. was awarded USD 1.5 million from the Department of Defense to evaluate NVR-291-R for enhanced nerve repair.

 

Gather more insights about the market drivers, restrains and growth of the U.S. Peripheral Nerve Injuries Market

 

Surgery Segmentation Insights

 

Based on surgery, direct nerve repair captured the largest market share of 42.67% in 2022. Direct nerve repair, also known as end-to-end neurorrhaphy, is considered the gold standard of surgical treatment for severe cases. These injuries result in a loss of communication ability due to malfunctioning motor and sensory nerves between peripheral organs and the central nervous system (CNS), leading to impairment. Direct nerve repair and autologous nerve grafts remain the gold-standard treatment options. While nerve conduits successfully provide ideal peripheral support for neuronal recovery, they are still insufficient. Additionally, the increasing number of traumatic accidents leading to peripheral nerve injuries may necessitate surgical intervention, further propelling segment growth.

 

However, the stem cell therapy segment is projected to expand at the fastest CAGR during the forecast period. Increased government initiatives and approvals for clinical trials are anticipated to fuel market growth. Approximately 2,754 clinics in the U.S. (as of 2021) offer stem cell therapy, and this number is likely to increase. A single stem cell injection can cost between USD 8,000 and 30,000. Although many of these clinics do not adhere to FDA regulations, stem cell therapy has demonstrated effectiveness in treating various conditions. The FDA has recommended stricter regulations for these cells due to safety concerns, which may lead to more stringent approval procedures for clinics in the future. These factors are expected to drive significant growth in the stem cell therapy segment.  

 

Order a free sample PDF of the U.S. Peripheral Nerve Injuries Market Intelligence Study, published by Grand View Research.

Thursday, 7 November 2024

Pet Insurance Market Trends: Growing Demand For Comprehensive Coverage

 The global pet insurance market is on a significant growth trajectory. Valued at USD 18.32 billion in 2024, it is projected to expand at a Compound Annual Growth Rate (CAGR) of 17.97% from 2025 to 2030. This growth is attributed to several key factors:


• Increasing Pet Population: The rising number of pets worldwide, particularly in urban areas, is driving the demand for pet insurance.

• Adoption of Insurance in Underpenetrated Markets: Many markets, especially in developing countries, have low pet insurance penetration rates. As awareness grows and economic conditions improve, more pet owners are opting for insurance.

• Rising Veterinary Care Costs: The cost of veterinary care, including treatments, surgeries, and medications, has been steadily increasing. Pet insurance provides financial protection against these expenses.

• Initiatives by Key Companies: Leading insurance providers are launching innovative pet insurance products and services, further stimulating market growth.

• Humanization of Pets: As pets are increasingly treated as family members, pet owners are more willing to invest in their well-being, including insurance coverage.
The 2024 State of the Industry (SOI) report by NAPHIA highlights the significant growth in pet insurance in North America. The number of insured pets in the region increased by 16.6% from 2022 to 2024, reaching 6.25 million.

 

Gather more insights about the market drivers, restrains and growth of the Pet Insurance Market 

 

Several factors are expected to further fuel the market's growth:

 

• Rising Incidence of Diseases: Cats and dogs are susceptible to various diseases, and the increasing prevalence of these conditions necessitates insurance coverage.

• Increasing Pet Adoption: The trend of pet adoption is on the rise, leading to a higher demand for pet insurance.

• Mitigating Expenses for Severe Medical Conditions: Insurance helps pet owners manage the financial burden associated with costly treatments for serious illnesses like cancer and accidental injuries.

• Surge in Demand for Veterinary Healthcare Facilities: The growing need for advanced veterinary care facilities, coupled with rising treatment costs, is driving the adoption of pet insurance.

 

Animal Segmentation Insights 

 

The dogs segment was the most popular in 2024, holding a significant 60.48% market share. This popularity is due to the global trend of dog adoption as pets. For example, the American Pet Products Association (APPA) study from 2023-2024 revealed that around 66% of U.S. households (approximately 86.9 million) own at least one pet. Dogs are the most insured pets, making up about 80% of the insured population, while cats account for the remaining 20%. The increasing number of pets in the region and the availability of various insurance policies to meet their diverse needs are expected to drive future market growth.

 

The other segment, including horses, small mammals, birds, etc., is projected to experience the fastest CAGR during the forecast period. Key factors contributing to this growth include rising pet adoption rates, expanding insurance company service offerings, and increasing disposable income in key markets. For instance, Agria introduced a new horse insurance plan covering veterinary fees up to EUR 10,000 (USD 10,841.1) annually. Additionally, in January 2024, Petco & Nationwide Pet Insurance partnered to launch a health insurance plan for various animals, including pet birds, exotic animals, dogs, cats, and others.

 

Order a free sample PDF of the Pet Insurance Market Intelligence Study, published by Grand View Research.